This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon Risks Fading Into Irrelevancy

SEATTLE ( TheStreet) -- Dendreon's (DNDN) latest quarterly disaster is a reminder that groundbreaking medicine doesn't necessarily translate into a successful or profitable business.

More and more, Dendreon is looking like Trimeris (TRMS), the once high-flying HIV drug company that unraveled because its novel HIV drug was too costly to make and too difficult to sell.

Provenge sales rose 30% to $64 million in the September quarter over June but Dendreon's expenses grew even more, most notable in a horrific 10% gross margin. [Gross margin in the second quarter was 42%.]

The unexpected rise in Provenge's cost of goods coupled with management's admission that sales of the prostate cancer therapy will slow down for the rest of the year sent Dendreon shares tumbling 23% to $8.10 Thursday's pre-market session.

Dendreon will not survive long with a 10% gross margin, or as cancer consultant Michael Becker of MD Becker Partners quipped on Twitter: "Dear Dendreon -- 'We lose a dollar on every sale but make it up on volume' is not a viable business model."

Provenge is a real scientific breakthrough -- a first-of-its-kind cancer "vaccine" that trains a patient's immune system to seek out and destroy tumor cells. But the high fixed costs and complex logistics required to manufacture and deliver the personalized therapy is proving to be Dendreon's undoing.

The company still insists it can reach cash-flow break even at $500 million in U.S. Provenge sales, but when that happens and whether Dendreon can ever achieve profit margins investors expect from drug makers isn't clear. The poor third-quarter financial picture doesn't inspire confidence.

Stepping back from the numbers, perhaps Dendreon's larger problem is that Provenge is already being eclipsed by other more promising prostate cancer therapies. When Provenge was being developed, drugs that extended the lives of patients with advanced prostate cancer were rare. Now, doctors have a growing menu of life-extending drugs to choose from, including Johnson & Johnson's (JNJ - Get Report) Zytiga and Sanofi's (SNY) Jevtana.

Looking ahead, the buzz in prostate cancer is about Algeta's Alpharadin, Medivation's (MDVN - Get Report) MDV3100 and Exelixis' (EXEL) cabozantinib, all still experimental but which also have the potential to dramatically extend prostate cancer survival.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
EXEL $5.85 0.00%
JNJ $95.08 0.00%
MDVN $39.23 0.00%
AAPL $109.50 0.00%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs